Aptevo Therapeutics Inc.
Nasdaq · CIK 0001671584 · Fiscal year end 1231
Latest reported period: Latest published period
Operating Income
$-6.8M
Net Income
$-6.7M
Eps Basic
-6.41
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-6.8M | - | - |
| Net Income | $-6.7M | - | - |
| Eps Basic | -6.41 | - | - |
| Eps Diluted | -6.41 | - | - |
| Cash And Equivalents | $14.5M | - | - |
| Total Assets | $19.9M | - | - |
| Total Liabilities | $8.3M | - | - |
| Shareholders Equity | $11.6M | - | - |
| Operating Cash Flow | $-8.0M | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | Aptevo Therapeutics Inc. | 2026-05-13 | 0001193125-26-221661 |
| 10-K | Aptevo Therapeutics Inc. | 2026-03-26 | 0001193125-26-126278 |
| 4 | Aptevo Therapeutics Inc. | 2025-11-12 | 0001193125-25-277771 |
| 10-Q | Aptevo Therapeutics Inc. | 2025-11-06 | 0001193125-25-269598 |
| 10-Q | Aptevo Therapeutics Inc. | 2025-08-11 | 0000950170-25-106247 |